Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Abraham Rutgers

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
The Journal of Allergy and Clinical Immunology|April 14, 2022
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunityLeanne P M van Leeuwen, Corine H GeurtsvanKessel, Pauline M Ellerbroek, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 11, 2025
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert PanelArsene M Mekinian, Sophie Georgin-Lavaille, Marcela A Ferrada, et al.
Blood Advances|December 11, 2025
Systematic functional validation of IKAROS variants from patients and laboratory-generated mutationsHye Sun Kuehn, Agustin Alejandro Gil Silva, Natchanun Klangkalya, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Annals of the Rheumatic Diseases|January 31, 2023
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseasesLuuk Wieske, Eileen W Stalman, P J Koos van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
JAMA|July 6, 2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis, Manu Shankar-Hari, Claire L Vale, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
The Journal of Allergy and Clinical Immunology|April 14, 2022
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunityLeanne P M van Leeuwen, Corine H GeurtsvanKessel, Pauline M Ellerbroek, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 11, 2025
American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert PanelArsene M Mekinian, Sophie Georgin-Lavaille, Marcela A Ferrada, et al.
Blood Advances|December 11, 2025
Systematic functional validation of IKAROS variants from patients and laboratory-generated mutationsHye Sun Kuehn, Agustin Alejandro Gil Silva, Natchanun Klangkalya, et al.
BMC Medicine|March 3, 2022
Risk factors associated with short-term adverse events after SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseasesLuuk Wieske, Laura Y L Kummer, Koos P J van Dam, et al.
Annals of the Rheumatic Diseases|January 31, 2023
Persistence of seroconversion at 6 months following primary immunisation in patients with immune-mediated inflammatory diseasesLuuk Wieske, Eileen W Stalman, P J Koos van Dam, et al.
Journal of Autoimmunity|January 9, 2023
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinationsKoos P J van Dam, Luuk Wieske, Eileen W Stalman, et al.
BMC Infectious Diseases|May 17, 2023
Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activityKoos P J van Dam, Adriaan G Volkers, Luuk Wieske, et al.
JAMA|July 6, 2021
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis, Manu Shankar-Hari, Claire L Vale, et al.
Annals of the Rheumatic Diseases|November 10, 2022
Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseasesEileen W Stalman, Luuk Wieske, Koos P J van Dam, et al.
The Lancet. Rheumatology|March 23, 2022
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort studyLuuk Wieske, Koos P J van Dam, Maurice Steenhuis, et al.
Pageof 10